Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

v3.19.3.a.u2
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2019
Income Taxes  
Schedule of components of loss before income taxes

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2019

    

2018

Domestic

 

$

(7,523,695)

 

$

(11,242,646)

Foreign

 

 

522,395

 

 

517,268

Total Loss Before Income Taxes

 

$

(7,001,300)

 

$

(10,725,378)

 

Schedule of components of income tax expense

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2019

    

2018

Deferred Taxes:

 

 

  

 

 

  

Federal

 

$

(4,182)

 

$

1,814

State

 

 

99,578

 

 

84,231

Total Deferred Taxes

 

$

95,396

 

$

86,045

Income Tax Expense

 

$

95,396

 

$

86,045

 

Schedule of effective income tax rate reconciliation

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

 

    

2019

    

2018

 

United States Federal Income Tax Rate

 

21.00

%  

21.00

%

State Taxes, Net of Federal Benefit

 

13.82

 

(0.38)

 

Permanent Differences

 

(4.18)

 

(1.48)

 

Change in Valuation Allowance

 

(37.40)

 

3.88

 

Research and Development Credits

 

6.53

 

1.06

 

Tax Rate Differential

 

(1.15)

 

(1.33)

 

Topic 606 Adoption

 

 —

 

(20.90)

 

Stock-Based Compensation

 

0.45

 

0.00

 

Other

 

(0.43)

 

(2.65)

 

Effective Tax Rate Expense

 

(1.36)

%  

(0.80)

%

 

Schedule of deferred tax assets and liabilities

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2019

    

2018

Net Deferred Tax Liability:

 

 

 

 

 

 

Net Operating Loss Carryforwards

 

$

15,230,646

 

$

13,601,705

Research and Development Credit Carryforwards

 

 

2,594,055

 

 

2,124,949

Capitalized Research and Development

 

 

6,521,705

 

 

5,861,675

Stock-Based Compensation

 

 

814,438

 

 

639,729

Depreciation and Amortization

 

 

170

 

 

(3,217)

Cash Versus Accrual Adjustments

 

 

1,738,482

 

 

2,069,985

Total Deferred Tax Assets

 

 

26,899,496

 

 

24,294,826

Valuation Allowance

 

 

(26,278,147)

 

 

(23,659,844)

Net Deferred Tax Asset

 

 

621,349

 

 

634,982

In-Process Research and Development

 

 

(986,713)

 

 

(904,950)

Net Deferred Tax Liability

 

$

(365,364)

 

$

(269,968)